* If you want to update the article please login/register
Participants will be encouraged to consider autopsy brain donation from the Alzheimer's Disease Neurology Initiative; and to investigate longitudinal and longitudinal cognitive and functional characteristics of people with early onset cognitive impairment and cognitively normal controls; and to compare baseline and longitudinal cognitive and behavioral characteristics, between EOAD and CN; and Late Onset Alzheimer's Disease; and to determine the correlations of longitudinal research and cognitive characteristics with multimodal imaging and biofluid markers that represent various aspects of the AD pathophysiological cascade.
Source link: https://clinicaltrials.gov/ct2/show/NCT03507257
This research aims to determine how tau affects the Human Central Nervous System and to test the possibility that tau increases with age and in diseases caused by the disruption of how tau normally works. Once identified, the researchers will examine Cerebral Spinal Fluid samples at various time points and determine how long the tau stays in the system for. Knowing the half-life of tau will help researchers design clinical trials that investigate tau and future therapeutic interventions for AD. The researcher will investigate the following amounts of leucine; Leucine infusion for 24 hours at a rate of 4 mg/kg/hour. If tau tautivity is apparent at this number, a second participant will be rewarded with a shorter infusion time and leucine infusion for 16 hours at a rate of 4 mg/kg/hour. If tau is present at this level, the researchers will process the samples immediately, if tau is apparent at this number. If tau is present at this level, a third participant will be given a smaller amount of leucine to identify tau. For leucine, the participant must have their meals monitored for the leucine present in our diets. After their first lumbar puncture, the participant is given three meals and three snacks in the 24 hours and then a BJC cafeteria breakfast. Once the amount and time of leucine infusion is appropriate, Young Normal Controls will repeat the infusion study for confirmation. On day one, participants will arrive at the Research Kitchen to pick up meals for two days, leucine for two days, as well as a diet diary. To determine physiological and pathophysiological changes in tau metabolism, we suggest using a newly developed tau kinetics test in AD patients and age-matched cognitively normal controls. The participants with normal CSF tau PET imaging findings from ten age-matched controls age 65 and over will be included in the analyses. We suspect that soluble tau production is increasing in AD as a result of an increase in aggregation rates and irreversible loss of soluble tau. In ten participants with late-onset AD dementia and ten cognitively healthy age-matched controls age 65 and over, we'll investigate the kinetics of CNS tau in ten participants with late-onset AD dementia and ten cognitively normal age-matched controls aged 65 and greater. Results from this tau SILK research will help clarify human CNS tau's dynamic kinetics in physiology and pathophysiology of tauopathies. CSF values in tau are correlated with cognitive decline in AD, but no such technique can test the assumption that tau kinetics of tau are altered in disease. To determine the tau kinetics in human central nervous system CNS, we now suggest using the newly developed tau SILK technique. e. g. , tau SILK method will be an important tool in future research to determine the pathophysiology of tau in AD and other neurodegenerative diseases. e. g. tau dynamics in vivo human soluble and aggregate tau dynamics can be investigated in-depth with tau SILK protocol and a novel tau PET T807 imaging system.
Source link: https://clinicaltrials.gov/ct2/show/NCT03938870
Given the looming specter, delaying the onset of AD symptoms and reducing the progression of the disease process has been a national public health concern. Randomized controlled trials of EXER in older adults have also demonstrated its beneficial effects on AD-relevant metrics such as brain glucose metabolism and memory/executive functions. Any legitimate attempts to reduce AD's rising burden of AD is likely to begin secondly, people with specific risk factors for AD. According to the Wisconsin Alzheimer's Prevention or the Wisconsin Alzheimer's Disease Research Center, the main aim of this study is to pilot a 26-week trial of EXER among asymptomatic, middle-aged adults with and without family history of AD enrolled in the Wisconsin Registry for Alzheimer's Prevention or the Wisconsin Alzheimer's Disease Research Center. AIM 2: Preliminarily characterize the effect of the EXER intervention on AD-related brain changes. Hypothesis: Compared to participants in the usual physical fitness group, those randomized to the enhanced physical fitness group will have preserved brain glucose levels. AIM 3: Preliminarily examine the biological mechanisms by which EXER affects brain health and cognition, as well as the individual difference factors that could influence EXER's effects. Hypotheses: People in the enhanced physical fitness group will experience significant rises in circulating neurotrophins and increased cardiorespiratory fitness, as well as improved cardiovascular endurance, and EXER's beneficial effects would be more pronounced among participants with reduced sedentary behaviors outside of the study. Hypothesis: Individuals in the enhanced physical fitness group will have significantly elevated cerebral blood flow, as well as improved endothelial function.
Source link: https://clinicaltrials.gov/ct2/show/NCT02384993
According to the subject and the subject's study partner, the tunes selected would need to be related to a previous meaningful, positive experience of the subject. Listening to nature sounds at the same time as the administration program would be included in the control program. Functional magnetic resonance imaging will be used to determine how brain networks are modulated by exposure to this music and how they relate to the clinical findings.
Source link: https://clinicaltrials.gov/ct2/show/NCT05309369
The primary aim of the study is to determine the effect of 12 weeks of 10 mg dapagliflozine once daily on cerebral NAA in AD patients. Throughout the study and every study visit to determine the incidence and severity of AEs and the rate of discontinuations due to AEs, the incidence and severity of AEs and the rate of discontinuation due to AEs will be recorded.
Source link: https://clinicaltrials.gov/ct2/show/NCT03801642
Both physiological and hormonal deregulations are a risk factor and a characteristic of Alzheimer's disease and frontotemporal dementia, and they occur early in the disease's course. The hypothalamus is a brain region that regulates metabolism and hormonal balances. The role of tanycytes has been established by our lab and the ERC consortium not only in the flow of neurohormones from neuroendocrine nerve terminals to the pituitary portal blood circulation, but also in the transport of circulating leptin into the hypothalamus. Hence, hypothalamic dysfunction in AD and FTD can arise either from neuroendocrine dysfunction, direct neuronal loss, or from inadequate transport to hormones like leptin. This research is to establish that leptin transport through tanycytes is early affected in FTD and AD, as well as correlates.
Source link: https://clinicaltrials.gov/ct2/show/NCT05288842
From the onset to large-scale perturbations, we want to see if people with mild Alzheimer's disease can learn fall prevention skills from the outside. The test will determine whether people with Alzheimer's disease can adapt to large-scale external disturbances and develop fall tolerance motor skills learned in Aim 1; and 3 to determine if people with Alzheimer's disease can generalize fall resistant skills to various contexts.
Source link: https://clinicaltrials.gov/ct2/show/NCT05205980
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions